News & Updates

Cell-cycle progression, but not phosphatase and tensin homolog, appears to significantly elevate the risk of metastasis in men with prostate cancer following Cancer of the Prostate Risk Assessment Post-Surgical adjustment, suggests a study.

In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).

Among prostate cancer patients on androgen deprivation therapy (ADT), a small prostate and higher reductions in testosterone levels appear to aggravate storage symptoms, a recent study has found.

In patients with non-muscle-invasive bladder cancer (NMIBC), high-grade (HG) recurrence after bacillus Calmette-Guérin (BCG) treatment is associated with T-cell exhaustion, according to a study.

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

Some social needs that are not properly addressed may contribute to the presence of overactive bladder (OAB) in adults, and these unmet needs can affect the overall management of OAB patients, suggests a recent study.

COVID-19 patients with chronic statin exposure appear to be at lower risk of developing acute kidney injury (AKI) during hospitalization in addition to having reduced levels of inflammation, as reported in a study.

Cefepime-taniborbactam (FTB) is significantly better than meropenem for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), according to results of the Cefepime Rescue with Taniborbactam in cUTI (CERTAIN-1) study presented at the recent ID Week 2022.